Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
K-Dur was a prescription extended-release potassium chloride product supplied in 10 mEq and 20 mEq tablets. FDA lists K-Dur in the discontinued drug product section and determined that its discontinuation was not related to safety or efficacy concerns. Extended-release potassium chloride tablets remain marketed under other names and generic labels.
read more about what was kdur ...Potassium chloride supplies potassium and chloride ions needed for normal cellular, nerve, muscle, and cardiac function. Oral replacement raises depleted body potassium stores when dietary measures or changes to potassium-lowering medicines are insufficient.
K-Dur was used to treat or prevent hypokalemia, including hypokalemia with metabolic alkalosis. Current extended-release potassium chloride products serve similar replacement roles when potassium-rich foods or reduction of a potassium-lowering medicine is insufficient.
The historical K-Dur label listed about 20 mEq daily for prevention of hypokalemia and 40 mEq to 100 mEq daily or more for treatment of potassium depletion, divided so that no more than 20 mEq was taken in one dose. Tablets were taken with meals and water rather than on an empty stomach.
Potassium chloride can cause potentially fatal hyperkalemia, particularly when potassium excretion is impaired or interacting medicines increase potassium. Solid extended-release products can also cause gastrointestinal ulceration, bleeding, obstruction, or perforation. Current products require serum potassium monitoring and careful use in kidney disease.
K-Dur contained extended-release potassium chloride.
K-Dur tablets contained 10 mEq or 20 mEq of potassium chloride.
No. FDA lists K-Dur as discontinued and determined that its discontinuation was not related to safety or efficacy concerns.
Yes. Potassium chloride extended-release tablets remain marketed under other names and generic labels.
Determination That APRESOLINE (Hydralazine Hydrochloride) Injectable and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. https://www.federalregister.gov/documents/2016/06/06/2016-13181/determination-that-apresoline-hydralazine-hydrochloride-injectable-and-other-drug-products-were-not. Date Accessed October 7, 2026.
K-Dur: Package Insert and Prescribing Information. https://www.drugs.com/pro/k-dur.html. Date Accessed October 7, 2026.
Potassium: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a601099.html. Date Accessed October 7, 2026.
Potassium Chloride. https://www.ncbi.nlm.nih.gov/books/NBK557785/. Date Accessed October 7, 2026.
Potassium Chloride Extended-Release Tablets Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0224e5b3-3c49-4e6e-aa78-1abcc6969246. Date Accessed October 7, 2026.